Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARDIZEM SR vs AMVAZ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes during depolarization, leading to negative inotropic, chronotropic, and dromotropic effects, and vasodilation.
AMVAZ (amivantamab-vmjw) is a bispecific monoclonal antibody that targets the extracellular domains of epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It inhibits ligand binding, receptor activation, and downstream signaling, leading to antibody-dependent cellular cytotoxicity and tumor cell death.
Hypertension,Angina pectoris due to coronary artery spasm (Prinzmetal's variant angina),Chronic stable angina (classic effort-associated angina)
FDA-approved for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
Oral: Initial dose 60-120 mg twice daily; titrate to maximum 360 mg/day divided into two doses.
Intravenous: 500 mg every 6 hours.
3.0-4.5 hours for diltiazem; metabolites (e.g., desacetyldiltiazem) up to 10 hours. Clinical context: dosing interval adjustment in hepatic impairment.
Terminal elimination half-life is 12-18 hours; prolonged in renal impairment (up to 30 hours) requiring dose adjustment.
Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism.
AMVAZ is a monoclonal antibody; it is degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes involved.
Renal: 2-4% unchanged; hepatic metabolism: ~60-70% (including active metabolites); fecal: ~30-40%.
Primarily renal excretion of unchanged drug (60-70%) and metabolites (10-20%); biliary/fecal excretion accounts for 15-25%.
Approximately 70-80%, primarily to albumin and alpha-1-acid glycoprotein.
98% bound to albumin primarily, with minor binding to alpha-1-acid glycoprotein.
3.1-5.1 L/kg; large Vd indicates extensive tissue distribution (e.g., myocardium, vascular smooth muscle).
0.2-0.3 L/kg, indicating minimal extravascular distribution and confinement to plasma volume.
Oral (sustained-release): approximately 40-50% due to first-pass metabolism; variable among formulations.
Oral bioavailability is 85-95%; reduced to 60-70% when taken with high-fat meals.
For GFR < 10 m L/min: Use with caution and reduce dose by 25-50%; consider extended dosing interval.
Cr Cl 30-50 m L/min: 250 mg every 6 hours; Cr Cl 15-29 m L/min: 250 mg every 12 hours; Cr Cl <15 m L/min: 250 mg every 24 hours; hemodialysis: 250 mg after dialysis.
Child-Pugh Class B: Reduce dose by 50%; Child-Pugh Class C: Use not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50%.
Safety and efficacy not established; no specific weight-based dosing guidelines available.
10 mg/kg IV every 6 hours; maximum 500 mg per dose.
Initial dose 60 mg twice daily; titrate slowly due to increased risk of bradycardia and hypotension.
Consider renal function; start at lower end of dosing range due to age-related decreased renal clearance.
None.
None
Cardiac conduction abnormalities: bradycardia, AV block, sick sinus syndrome,Heart failure: use with caution in patients with compromised ventricular function,Hypotension,Hepatic impairment,Concomitant use with beta-blockers may increase risk of bradycardia and AV block,Abrupt discontinuation may exacerbate angina
Infusion-related reactions (IRRs): premedicate and monitor during infusion; interrupt or discontinue if severe.,Interstitial lung disease (ILD)/pneumonitis: monitor for new or worsening respiratory symptoms; withhold or permanently discontinue.,Dermatologic adverse reactions (rash, dry skin, pruritus): manage with topical corticosteroids, emollients, and oral antihistamines; consider dose modification.,Ocular toxicity: monitor for keratitis, uveitis; refer to ophthalmology if symptoms develop.,Embryo-fetal toxicity: can cause fetal harm; advise effective contraception.
Sick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker),Second- or third-degree AV block (except in patients with a functioning artificial ventricular pacemaker),Hypotension (systolic blood pressure < 90 mm Hg),Acute myocardial infarction with pulmonary congestion,Known hypersensitivity to diltiazem
None
Grapefruit and grapefruit juice increase diltiazem levels by inhibiting CYP3A4 metabolism; avoid concurrent use. No other significant food restrictions. Alcohol may enhance hypotensive effects and increase risk of dizziness.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing amiodarone levels and risk of toxicity. Limit alcohol consumption due to potential hepatotoxicity. High-fat meals may increase absorption; take consistently with or without food.
FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, diltiazem has been shown to cause embryofetal toxicity (skeletal abnormalities, reduced fetal weight) at doses 5-10 times the maximum recommended human dose. Risk to fetus cannot be ruled out; use only if potential benefit justifies potential risk.
No human data available; in animal studies, no teratogenicity observed at clinically relevant doses. First trimester: data insufficient to assess risk. Second and third trimesters: no known fetal harm.
Diltiazem is excreted into human breast milk at low concentrations. Estimated infant dose is <1% of maternal weight-adjusted dose. M/P ratio not established. Although risk to nursing infant is likely low, caution is advised. Monitor infant for bradycardia, hypotension, and feeding difficulties.
No data on excretion in human milk; M/P ratio unknown. Caution recommended; benefits of breastfeeding should be weighed against potential risk to infant.
No specific dose adjustment guidelines for pregnancy; however, pharmacokinetic changes in pregnancy (increased volume of distribution, altered hepatic metabolism) may require dose titration based on clinical response and tolerability. Start at lowest effective dose and monitor closely.
No specific dose adjustments required in pregnancy; pharmacokinetic changes not well-characterized. Use lowest effective dose and monitor clinical response.
Cardizem SR is a sustained-release calcium channel blocker indicated for hypertension and angina. Onset: 2-3 hours, duration: 12-24 hours. Avoid concurrent use with beta-blockers due to risk of bradycardia and heart block. Contraindicated in sick sinus syndrome (unless pacemaker), second- or third-degree AV block, hypotension (SBP <90 mm Hg), and acute MI with pulmonary congestion. Monitor liver function and renal function; dose adjustment needed in hepatic impairment. Use caution in patients with decreased left ventricular function (ejection fraction <40%). Do not crush or chew capsules; swallow whole.
AMVAZ (amiodarone) has a long half-life (up to 107 days) and can cause thyroid, pulmonary, hepatic, and skin toxicity. Monitor thyroid function (TSH, T3, T4), liver enzymes (ALT, AST), and perform baseline pulmonary function tests and chest X-ray. Corneal microdeposits are common and may cause visual halos; usually reversible. Administer loading dose to achieve therapeutic effect more quickly. Avoid use with grapefruit juice as it increases drug levels.
Take this medication exactly as prescribed, with or without food, at the same time each day.,Swallow the capsule whole; do not crush, chew, or open it.,Avoid grapefruit and grapefruit juice while on this medication; they can increase the drug's effect and risk of side effects.,Do not stop taking this medication suddenly; abrupt discontinuation may worsen chest pain or increase blood pressure.,Contact your healthcare provider if you experience slow heartbeat, fainting, dizziness, shortness of breath, or swelling of the legs/ankles.,Limit alcohol consumption as it may increase the risk of side effects such as dizziness or fainting.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Keep all appointments to check your blood pressure and heart rhythm.
Take AMVAZ exactly as prescribed; do not stop without consulting your doctor.,Avoid grapefruit and grapefruit juice while taking this medication.,Report any new or worsening shortness of breath, cough, chest pain, or palpitations immediately.,Notify your doctor if you experience vision changes, yellowing of skin/eyes, dark urine, or unusual fatigue.,Use effective contraception during treatment and for at least 6 months after stopping.,Avoid excessive sun exposure; use sunscreen and protective clothing due to risk of skin discoloration and photosensitivity.,Do not take over-the-counter medications or herbal supplements without checking with your doctor.,Regular blood tests and eye exams are necessary while on this medication.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARDIZEM SR vs AMVAZ, answered by our medical review team.
CARDIZEM SR is a Calcium Channel Blocker that works by Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes during depolarization, leading to negative inotropic, chronotropic, and dromotropic effects, and vasodilation.. AMVAZ is a Calcium Channel Blocker that works by AMVAZ (amivantamab-vmjw) is a bispecific monoclonal antibody that targets the extracellular domains of epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It inhibits ligand binding, receptor activation, and downstream signaling, leading to antibody-dependent cellular cytotoxicity and tumor cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARDIZEM SR and AMVAZ depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARDIZEM SR is: Oral: Initial dose 60-120 mg twice daily; titrate to maximum 360 mg/day divided into two doses.. The standard adult dose of AMVAZ is: Intravenous: 500 mg every 6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARDIZEM SR and AMVAZ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARDIZEM SR is classified as Category C. FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, diltiazem has been shown to cause embryofetal toxicity (skeletal abnormalities, reduced fetal we. AMVAZ is classified as Category C. No human data available; in animal studies, no teratogenicity observed at clinically relevant doses. First trimester: data insufficient to assess risk. Second and third trimesters:. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.